trauma-care
(3)
Cayuga Biotech
Cayuga Biotech is a clinical-stage biotech developing first-in-class therapeutics that stop life-threatening bleeding by accelerating the body's own clotting cascade. Its lead candidate, CAY001, is a synthetic polyphosphate-silica nanoparticle (polyP-SNP) designed to work where conventional hemostatic agents fall short - non-compressible hemorrhage from trauma, surgery, blood thinners and inherited bleeding disorders. Founded on research from UC Santa Barbara, the company harnesses polyphosphate, a natural cofactor stored in platelets, to normalize thrombin production and speed clot formation without slowing clot breakdown.
Abhishek Ramkumar
Abhishek Ramkumar is the founder and CEO of Abram Scientific, a Menlo Park medtech company building CoagCare, a handheld point-of-care platform that reads the full blood-clotting story from a single drop in under ten minutes. A biomedical engineer with a PhD from Cornell and a B.Tech from IIT Bombay, he spent years at PARC and Blue Highway inventing diagnostic and surgical devices before turning a hard physics problem - measuring blood viscoelasticity and density in a vibration-proof wireless meter - into 17 granted patents and an $11.75M Series A led by Octapharma in 2026. His pitch is simple and life-or-death: get the right transfusion to the right patient at the right time, whether that patient is on an operating table or in a MEDEVAC helicopter.
Abram Scientific
Abram Scientific is a Menlo Park, California medical-device company building CoagCare, a portable point-of-care platform that reads the full blood-coagulation cascade - from clot formation through fibrinolysis - from a single drop of blood in under 10 minutes. By measuring blood viscoelasticity and density on single-use test cards inside a vibration-insensitive handheld meter, CoagCare aims to move coagulation testing out of the central lab and into trauma bays, ambulances, and MEDEVAC helicopters, helping clinicians decide the right transfusion or therapy at the right time.